| Income statement (USD) | Q4 2026 ended May 31, 2026 | Q3 2026 ended Feb 28, 2026 | Q2 2026 ended Nov 30, 2025 | Q1 2026 ended Aug 31, 2025 | Q4 2025 ended May 31, 2025 | Q3 2025 ended Feb 28, 2025 | Q2 2025 ended Nov 30, 2024 | Q1 2025 ended Aug 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 86.61M | 78.42M | 79.43M | 75.71M | 80.16M | 72.00M | 72.84M | 67.49M |
| Cost of revenue | 39.83M | 36.94M | 34.65M | 33.85M | 37.94M | 33.15M | 32.94M | 30.77M |
| Gross profit | 46.77M | 41.48M | 44.78M | 41.86M | 42.22M | 38.86M | 39.91M | 36.72M |
| Research and development | 8.18M | 7.08M | 7.77M | 6.42M | 6.59M | 6.91M | 6.43M | 6.29M |
| Operating expenses | 56.97M | 54.43M | 50.91M | 52.51M | 48.01M | 48.83M | 51.00M | 49.82M |
| Operating income | -10.20M | -12.95M | -6.13M | -10.66M | -5.79M | -9.97M | -11.09M | -13.10M |
| EBITDA | -4.60M | -7.36M | -378.0K | -4.64M | 45.0K | -3.65M | -4.23M | -6.31M |
| Income before tax | -11.04M | -8.07M | -6.36M | -10.84M | -6.11M | -4.41M | -10.85M | -12.66M |
| Income tax | 370.0K | 12.0K | -5.0K | 65.0K | -60.0K | -2.0K | -110.0K | 133.0K |
| Net income | -11.40M | -8.08M | -6.35M | -10.90M | -6.05M | -4.41M | -10.74M | -12.80M |
| EPS | -0.27 | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 | -0.26 | -0.31 |
| EPS (diluted) | -0.27 | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 | -0.26 | -0.31 |
| Diluted shares | 58.7K | 41.60M | 41.54M | 41.17M | 43.6K | 40.85M | 40.92M | 40.65M |
From Angiodynamics Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.